#China #Hangzhou #Investor Relations #medical technology #Zylox-Tonbridge

Zylox-Tonbridge Achieves Recognition in Extel 2026 Survey

On June 8, 2026, Zylox-Tonbridge Medical Technology Co., Ltd. earned the prestigious title of Most Honored Company in the Extel 2026 Asia Executive Team Survey, reflecting the firm’s strong reputation within the international investment community. Zylox-Tonbridge, which trades on the Hong Kong Stock Exchange under the symbol 2190, specializes in neurovascular and peripheral vascular intervention solutions. This recognition highlights essential aspects of the company, including its governance standards, management quality, transparent communication with investors, and long-term commitment to growth and stability.

The survey in which Zylox-Tonbridge was honored saw participation from over 5,500 investors, including portfolio managers and analysts who voted on various companies based on their executive teams and best practices. Notably, the company stood out not only as a Most Honored Company but also received accolades in several categories within the Healthcare Equipment & Services sector. These included Best CEO, Best CFO, Best Investor Relations Program, Best Investor Relations Team, and Best Investor Relations Professional.

Extel, known for its comprehensive rankings, gathers insights primarily from prominent global investors passionate about corporate governance, investor relations, and corporate transparency. Dr. Jonathon Zhao, the Chairman and CEO of Zylox-Tonbridge, expressed gratitude for the recognition, stating, “This honor reflects the capital market's recognition of our corporate governance standards and management team.” He further emphasized the company's focus on long-term value creation and an ongoing commitment to improving investor relations management.

Zylox-Tonbridge's rapid growth and sustained innovation trajectory impress the market, reassuring investors of its operational soundness and governance quality. Looking ahead, the company plans to continue its strategy based on innovation and international expansion, with an unwavering focus on developing high-quality medical devices that cater to patient needs worldwide. Zylox-Tonbridge, founded in 2012 and headquartered in Hangzhou, China, is on a mission grounded in its philosophy of “Innovation for Quality Life.” Their dedication towards exceptional medical solutions demonstrates their commitment to quality and accessibility, which further validates their esteemed status.

As the landscape of medical technology evolves, Zylox-Tonbridge remains at the forefront, striving to deliver innovative solutions while enhancing their global outreach and product effectiveness. The recognition by Extel serves as both a testament to the company's achievements and a motivator for future endeavors in delivering quality healthcare solutions. To learn more about Zylox-Tonbridge and its products, visit www.zyloxtb.com.